Abstract
Autoimmune liver diseases are chronic inflammatory conditions leading to an etiologically undefined immunemediated attack aimed at hepatocytes and the biliary epithelium. Drugs used in autoimmune liver disease such as ursodeoxycholic acid, prednisolone and azathioprine are not effective in all patients, therefore, new therapeutic approaches are needed for autoimmune liver diseases that are refractory to standard therapy. Biotherapy is a thriving area of research and development, and is used in the treatment of chronic autoimmune liver diseases. However, to date, there is no clinically validated standard biotherapy for autoimmune liver diseases. Thus, future clinical trials are required to evaluate the effectiveness and safety of biotherapy before this approach can be used in routine clinical practice for the therapy of autoimmune liver diseases. This article provides an overview of emerging biotherapy for autoimmune liver diseases.
Keywords: Autoimmune hepatitis (AIH), autoimmune liver disease, biotherapy, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC).
Current Pharmaceutical Biotechnology
Title:Biotherapy for Autoimmune Liver Diseases
Volume: 15 Issue: 6
Author(s): Mei Liu, Yu Chen, Sujun Zheng, Zhongping Duan and Jian-Ying Zhang
Affiliation:
Keywords: Autoimmune hepatitis (AIH), autoimmune liver disease, biotherapy, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC).
Abstract: Autoimmune liver diseases are chronic inflammatory conditions leading to an etiologically undefined immunemediated attack aimed at hepatocytes and the biliary epithelium. Drugs used in autoimmune liver disease such as ursodeoxycholic acid, prednisolone and azathioprine are not effective in all patients, therefore, new therapeutic approaches are needed for autoimmune liver diseases that are refractory to standard therapy. Biotherapy is a thriving area of research and development, and is used in the treatment of chronic autoimmune liver diseases. However, to date, there is no clinically validated standard biotherapy for autoimmune liver diseases. Thus, future clinical trials are required to evaluate the effectiveness and safety of biotherapy before this approach can be used in routine clinical practice for the therapy of autoimmune liver diseases. This article provides an overview of emerging biotherapy for autoimmune liver diseases.
Export Options
About this article
Cite this article as:
Liu Mei, Chen Yu, Zheng Sujun, Duan Zhongping and Zhang Jian-Ying, Biotherapy for Autoimmune Liver Diseases, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/138920101506140910145539
DOI https://dx.doi.org/10.2174/138920101506140910145539 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Spongiane Diterpenoids
Current Bioactive Compounds Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates
Current Topics in Medicinal Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Trends in Cell-Based Electrochemical Biosensors
Current Medicinal Chemistry Pixuvri<sup>®</sup> (Pixantrone Dimaleate, BBR 2778): From Lab to Market
Current Organic Chemistry The Centrosome: A Target for Cancer Therapy
Current Cancer Drug Targets Granulocyte Colony-stimulating Factor as the Expecting Sword for the Treatment of Severe Sepsis
Current Pharmaceutical Design The Challenge of a “Functional Cure” for AIDS by Gene Modified HSCT Therapy
Current Stem Cell Research & Therapy Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Synthesis, <i>In Vitro</i> Evaluation, Molecular Docking and DFT Studies of Some Phenyl Isothiocyanates as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Immunotoxins in the Treatment of Hematologic Malignancies
Current Drug Targets Heart Transplantation for Congenital Heart Disease in the First Year of Life
Current Cardiology Reviews A Review on Hemisynthesis, Biosynthesis, Biological Activities, Mode of Action, and Structure-Activity Relationship of Podophyllotoxins: 2003- 2007
Current Medicinal Chemistry Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
Current Cancer Drug Targets Interstitial Lung Disease Associated with Collagen Vascular Disease
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Indication of Bevacizumab for Cerebral Radiation Necrosis
Recent Patents on Anti-Cancer Drug Discovery Going 3D – Cell Culture Approaches for Stem Cell Research and Therapy
Current Tissue Engineering (Discontinued)